Timing hypothesis (menopausal hormone therapy)
The timing hypothesis is a theory in menopausal hormone therapy that suggests the timing of hormone therapy initiation can influence its effectiveness and risks. This hypothesis is based on the observation that the effects of hormone therapy can vary depending on the time of initiation relative to menopause onset.
Background[edit]
The timing hypothesis was proposed to explain the conflicting results of the Women's Health Initiative (WHI) and the Heart and Estrogen/progestin Replacement Study (HERS). The WHI found that hormone therapy increased the risk of coronary heart disease (CHD), while the HERS found no effect. The timing hypothesis suggests that these discrepancies may be due to differences in the timing of hormone therapy initiation relative to menopause onset.
Evidence[edit]
Several studies have provided evidence supporting the timing hypothesis. For example, a reanalysis of the WHI data found that women who started hormone therapy closer to menopause had a lower risk of CHD than those who started later. Similarly, a meta-analysis of 23 randomized controlled trials found that hormone therapy initiated within 10 years of menopause onset was associated with a reduced risk of CHD and all-cause mortality.
Criticism[edit]
Despite the evidence supporting the timing hypothesis, it has been criticized for several reasons. Some argue that the evidence is not strong enough to change clinical practice, while others point out that the hypothesis does not explain all of the discrepancies between the WHI and HERS results. Furthermore, some researchers have raised concerns about the potential risks of hormone therapy, regardless of when it is initiated.
See also[edit]
- Menopause
- Hormone replacement therapy
- Women's Health Initiative
- Heart and Estrogen/progestin Replacement Study
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
